Aquestive to Present Anaphylm Data at ACAAI
The biopharmaceutical company will share multiple oral and poster presentations on its investigational oral epinephrine film at the November 2026 meeting in Phoenix.
Updated on Nov. 5, 2026 in Allergies
Aquestive Therapeutics will present several oral and poster presentations at the 2026 ACAAI Annual Meeting, held November 12-16 in Phoenix, Arizona. The presentations evaluate the pharmacokinetic and pharmacodynamic profile of its investigational sublingual film, Anaphylm (dibutepinephrine).
Why it matters
Anaphylm is an investigational product that, if approved by the FDA, would be the first and only oral rescue medication for severe allergic reactions, including anaphylaxis. The data presented at the allergy and immunology meeting will be examined by clinicians and researchers evaluating epinephrine delivery options.
The presentations are scheduled for November 13-14, 2026, with abstracts published online November 12. The data cover patients with and without symptoms of a Type I allergic reaction, but no efficacy results have been released yet.
The players
Aquestive Therapeutics
Aquestive Therapeutics is a biopharmaceutical company headquartered in Warren, New Jersey, that develops oral drug delivery products.
American College of Allergy, Asthma and Immunology (ACAAI)
The American College of Allergy, Asthma and Immunology is a professional medical society that hosts an annual meeting for allergists and immunologists.
The details
Aquestive will deliver an oral presentation on dibutepinephrine pharmacokinetics and pharmacodynamics, plus two posters: one on healthcare provider perspectives on epinephrine delivery in anaphylaxis and one on pharmacodynamic effects of its AQST-109 sublingual film. Anaphylm is a polymer matrix-based epinephrine prodrug that requires no water or swallowing for administration.
Timeline
November 12, 2026: Abstracts become available at annualmeeting.acaai.org.
November 13, 2026, 3:05 pm MST: Karen Rance presents a poster on healthcare provider perspectives.
November 13, 2026, 3:20 pm MST: David B.K. Golden presents a poster on AQST-109.
November 14, 2026, 4:43 pm MST: Jay A. Lieberman delivers an oral presentation on dibutepinephrine pharmacokinetics.
Health Landscape
Current anaphylaxis treatment relies on injectable epinephrine auto-injectors, which Aquestive's Anaphylm film seeks to supplement with an oral, needle-free option. The company's AdrenaVerse platform, which includes more than 20 epinephrine prodrugs, reflects an effort to expand delivery formats beyond injection.
If approved, Anaphylm could offer people at risk of severe allergic reactions an oral, water-free option that requires no swallowing. The presentations are early-stage pharmacology data and do not yet indicate when the product will be available.
The takeaway
People with allergies should keep their prescribed epinephrine on hand and follow their current anaphylaxis action plan. New delivery formats remain investigational until regulators review the full data.
What happens next
The ACAAI Annual Meeting runs November 12-16, 2026, with Aquestive's presentations scheduled November 13-14; abstracts will be posted online November 12.
Further reading
Explore more on Allergies coverage for context on how new treatment options are developing.
More information
Abstracts for the presentations are available at ACAAI annual meeting abstracts.
Source note: This article includes information reported by The Manila times.
